drugset / Trial / NCT03779035
Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection
RandomizedParallel-groupOpen-labelTreatment
Summary
This prospective, open-Label, comparative, randomized, controlled phase III trial was designed to compare the clinical performance of gemcitabine with capecitabine vs. capecitabine alone for patients with biliary tract cancer (BTC) after curative resection.
Timeline
- Start
- 2018-12-15
- Primary completion
- 2020-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |